Histone-modifying enzymes play key roles in transcriptional regulation and control major cellular processes such as the cell cycle, 1,2 stem cell maintenance, and differentiation. 3, 4 These enzymes function within multisubunit protein complexes that target acetyltransferases and deacetylases to specific gene loci to provide cell-and tissue-specific regulation of developmental processes. The combinatorial effects of epigenetic marks influence the accessibility of transcription factor binding sites and can control specific regulatory programs. Epigenetic dysregulation of chromatin is actively studied in both development and cancer and alterations in histone acetylation are implicated in regulating stem cells and differentiation. 5 In this report, we describe four individual cases in which the presence of de novo mutations suggested that all of them had a previously unrecognized rare autosomal dominant disease. Their syndrome was discovered only after the more routine implementation of clinical exome sequencing (CES) for individuals with potential genetic diseases but without a clear diagnosis. 6, 7 All four individuals were sequenced with their parents (trio-CES) to empower the identification of de novo mutations, and all four had de novo nonsense mutations in KAT6A. Individuals 1-II-1, 2-II-2 and 3-II-1 underwent trio-CES at the Clinical Genomics Center at UCLA and 4-II-1 underwent trio-CES at GeneDx (Figure 1 ). CES at UCLA was performed using standard protocols from genomic DNA extraction to data analysis 6, 8 in a CLIA-certified laboratory. In these individuals, we identified 21,937 to 23,099 high-quality single nucleotide, insertion, and deletion variants (SNVs and indels) per individual. On the basis of the clinical history of probands 1-II-1, 2-II-2, and 3-II-1, each referring physician generated a list of phenotype keywords that was used to retrieve a primary genelist from the Human Gene Mutation Database (HGMD) and Online Mendelian Inheritance of Man (OMIM). No likely pathogenic variants were identified within any known disease genes in the three individuals sequenced at UCLA. No rare homozygous variants or compound heterozygous variants were identified for recessive disorders, and no variants were identified in known autosomal dominant disorders in any of the individuals. All trio-CES cases are evaluated for potential de novo mutations, and on average each trio-CES case identifies 1.1 de novo, rare, and damaging variants in the proband. In each of the cases presented here, all of them had a de novo mutation in KAT6A, and two cases had an additional high-quality de novo variant of uncertain significance in other non-clinical genes. Because KAT6A had not been previously reported in association with a genetic disease, this variant was initially classified in all reports as a variant of uncertain significance. 9 However, three of the four individuals (1-II-1, Figure 1 ). Both transition mutations are at CpG bases. All de novo KAT6A mutations identified by the UCLA CGC were confirmed by Sanger sequencing in the proband and his/her parents ( Figure 2C ), and all mutations are predicted to cause truncation within the acidic domain of the KAT6A protein, leaving the HAT domain intact ( Figure 1C ). Within 1,815 clinical exomes sequenced at UCLA, no other nonsense, frameshift, or splice-site variants in KAT6A were observed. The missense variant rate estimated from the exome variant server (EVS) data in KAT6A is 0.03 (57 rare [<0.1%] variants predicted to be damaging by Pol- yPhen2 out of 2004 amino acids). This is similar to the missense variant rate of other HAT-encoding genes (KAT6B, CREBBP, and EP300) that are known to cause rare autosomal dominant disorders when mutated and suggests that deleterious missense variations in KAT6A are selected against in the human population.
In the Exome Aggregation Consortium (ExAC), which houses nearly 65,000 exomes (including EVS), there are five heterozygous variants (see Table S1) that are predicted to result in a truncated protein and each variant is present in heterozygous form in one individual out of 65,000 exomes. None of the five variants are present in the homozygous form. Two variants are located in intronic regions of the canonical transcript (NM_001099412.1). Of the remaining three variants, variant p.Gln1995* is located ten amino acids from the C terminus and none of the functional domains are disrupted so we predict that the variant is not likely to be pathogenic. However, the remaining two variants p.Ser1113* and p.Ile368_Thr369ins* are located upstream and disrupt multiple known functional protein domains and, based on our cohort, are predicted to be pathogenic. However, these variants are exceedingly rare and without having a complete phenotype from either individual it is unclear whether the individual might be mildly affected with a similar syndrome as described here.
Because the KAT6A variants in the three individuals identified through UCLA CES were exceedingly rare, de novo, and deleterious, the clinical histories of the probands were more closely evaluated in order to determine potential overlapping features in their phenotypes. A systematic review of the four children with their treating physicians found several cardinal features present in all three individuals, as well as features that exhibited variable expressivity. Some differences in clinical description were noted between the probands. Clinical features are summarized in Table 2 , and the results of genetic, metabolic, and radiographic testing are summarized in Table S2 .
Proband 1-II-1 was the first child of non-consanguineous parents conceived through in vitro fertilization. The pregnancy was uncomplicated, with normal screening ultrasounds. He was delivered via cesarean section and at birth was noted to be microcephalic with OccipitalFrontal circumference (OFC) (32 cm, Z ¼ À2.1) but he had a normal weight and length. At 3 months, poor growth was noted with poor swallow function. Nasogastric tube was placed at 8 months followed by gastric tube due to recurrent aspiration pneumonias for which he was hospitalized several times. A large secundum atrial septal defect (ASD) was repaired at age of 5. He had dysmorphic features (Figure 1 ), brachydactyly, intermittent esotropia, and developmental delay. He was not able to sit independently until 1 year of age and at 3.5 years he remained unable to walk and had absent speech.
Proband 2-II-2 was born at 37 weeks as the second child to non-consanguineous parents. Pregnancy was complicated by preterm labor beginning at 20 weeks and right hydronephrosis diagnosed by fetal ultrasound. Birth weight was normal, but length (45 cm, Z ¼ À3.1) and OFC (34 cm, Z ¼ À2.1) were below the third percentile. At birth she had a cleft palate, intestinal malrotation, ventricular septal defect, bronchomalacia, and esotropia. MRI showed no structural brain defects. Since birth she has been hospitalized numerous times for recurrent urinary tract and respiratory infections. At 9 months, a right pyeloplasty was performed with improvement of recurrent urinary tract infections. At 11 months, cleft palate was repaired and myringotomy tubes were placed for recurrent ear infections. She was diagnosed with autism spectrum disorder at the age of 2 years and received behavioral therapy, which improved behavior, social interactions, and eye contact. Developmentally, she sat independently at 2 years of age and pulled to stand at 2 years 11 months. At the time of last examination at 3 years of age she was non-verbal.
Proband 3-II-1 was born at 42 weeks gestation as the first child of non-consanguineous parents. During the pregnancy, the mother had preterm bleeding and remained on bed rest with suspected placental infarct at 36 weeks. Routine maternal serum screening was normal, and prenatal ultrasounds showed intrauterine growth restriction but were otherwise normal. At birth, weight (1.87 kg, Z ¼ À3.3), length (47.6 cm, Z ¼ À2.6), and head circumference (exact OFC unknown) were less than the third percentile. Postnatally, he had bilateral cryptorchidism, strabismus, feeding difficulty, dysmorphic facial features, and axial hypotonia. He was noted to have global developmental delay without structural neurological defects. He developed a social smile at 3 months, sat independently at 1 year, and walked at 4 years 6 months of age. His height and OFC remained less than the third percentile for age but weight increased appropriately. At 5 years old, he was not communicating verbally.
Proband 4-II-1 was born at 37 weeks to non-consanguineous parents after an uncomplicated pregnancy with normal maternal serum screening and ultrasounds. At birth, she was microcephalic (OFC ¼ 32, Z ¼ À3.0) but with normal weight and length. She was noted to have distinct facial features, ASD, chronic ear infections requiring tympanic tube placement, insomnia-type sleep disturbances, and varying degrees of hypotonia and dystonia. Developmentally, she sat independently by one year of age and by 4.5 years was walking independently but remained without verbal communication.
All four individuals exhibited primary microcephaly with a head circumference less than third percentile (Z scores in Table 1 ), global developmental delay, profound speech delay, and dysmorphic craniofacial features ( Figure 1B , Table 2 ). Photographs of probands from families 1, 3, and 4 were shown to two experienced clinical geneticists and dysmorphologists who noted similar facial features suggestive of disruption of a common developmental pathway. These include a thin upper lip, epicanthal folds, broad nasal bridge, and large forehead. Other medical problems that were present to varying degrees in at least three out of the four children include feeding difficulties, gastric reflux, cardiac septal defects, ocular anomalies, and abnormalities in muscle tone. Many of the features exhibited in these children exist in other well-characterized 6 With increased application of CES to children and undiagnosed adults with developmental delay, mutations in KAT6A are likely to be identified in many other children, which will permit better characterization of the phenotypic spectrum affiliated with KAT6A mutations. In order to understand the molecular mechanisms underlying the phenotype in these children, we obtained dermal fibroblasts from probands 1-II-1 and 3-II-1 and expanded them in culture as in previous studies.
12 All procedures followed were in accordance with the ethical standards of the UCLA IRB and proper informed consent was obtained. To assess the presence of nonsense-mediated decay of the mutant transcript, we sequenced cDNA from fibroblasts to determine whether both the reference and mutant transcript were present from the affected probands 1-II-1 and 3-II-1 (Figure 2A) . In 1-II-1, the wild-type (WT) and mutant transcript (c.3385C>T) were present at equal levels. However in 3-II-1, the mutant transcript is decreased there appears to be an allelic imbalance, with less of the mutant transcript compared to the control. Quantitative real-time Taqman PCR for KAT6A and GAPDH (Life Technologies, 4331182 and 4331182) was performed in triplicate, and no significant decrease in KAT6A mRNA transcript was observed between control fibroblasts and those from probands 1-II-1 and 3-II-1 ( Figure 2B ). Both the normal levels of KAT6A mRNA and the equal presence of the WT and mutant transcripts by Sanger sequencing in proband 1-II-1 indicate that mutations in the terminal exon do not result in nonsense-mediated decay. 11 The nonsense variant c.3070C>T is located in the non-terminal exon (as in proband 3-II-1) demonstrates allelic imbalance in favor of the WT allele but without any significant decrease in KAT6A transcript levels. Therefore, at basal levels, there is no evidence for substantial nonsense-mediated decay for either KAT6A variant. However, we cannot rule out the presence of nonsense-mediated decay or other mechanisms influencing RNA stability when KAT6A is upregulated. KAT6A (a.k.a., MYST3, MOZ) is a lysine (K) acetyltransferase that is located on chromosome 8p11.2 and is a member of the MYST family of proteins. All members of the MYST family contain a highly conserved catalytic histone acetyl transferase (HAT) domain with roles in both histone lysine acetylation 13 and protein lysine acetylation. 14 Both histone acetylation and p53 pathways have been previously shown to control a wide range of processes such as DNA repair and replication, metabolism, cell mobility, stem cell maintenance, 24 and senescence. [25] [26] [27] To test whether global histone acetylation patterns were perturbed by KAT6A mutations, we performed histone extraction 28 on control fibroblasts (ATCC) and dermal fibroblasts from proband 1-II-1. Histone extractions were subject to Western blot and probed using antibodies to core histone 3 and specific acetylated forms of histone 3 as follows: H3K9, H3K14, H3K18, H3K27, and H3K56 (Acetyl-Histone H3 Antibody Kit, Cell Signaling 9927), core histones 2A, 2B, and 4 and acetylated H2AK5, H2BK5 and H4K8 (B) Quantitative real-time PCR in fibroblasts from proband 1-II-1 and 3-II-1 showed no significant decrease in KAT6A mRNA compared to control fibroblast samples. All samples were run triplicate and normalized against GAPDH. All samples were compared to biological controls and the (2 (-ddCt) ) method was used for statistical analysis. 
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(Acetyl-Histone Antibody Sampler Kit, Cell Signaling 9933). All experiments were performed in duplicate. We observed a decrease in H3K9 acetylation and increase in H3K18 acetylation in Proband 1-II-1 fibroblasts compared to the control fibroblasts ( Figure 3A) . No histone acetylation was observed in H3K14, H3K27, H3K56, H2AK5, and H2BK5 in either cell type, and no change in histone acetylation was observed in H4K8 (data not shown). KAT6A acetylation of P53 has also been shown to regulate downstream P53 signaling. 15 KAT6A acetylates residues K382 and K120 on P53 15 in vivo and deletion constructs demonstrated the requirement for both the HAT domain and the Serine and Methionine (SM) rich domain for interaction with P53. Therefore, we hypothesized that the truncation of the C terminus of KAT6A results in loss of the SM domain leading to decreased P53 acetylation and dysregulation of downstream P53 signaling. We generated RNA sequencing libraries using Illumina TruSeq RNA sample prep V2 in duplicate, and libraries were pooled and sequenced on Illumina HiSeq (UCLA Clinical Microarray Core). All reads were aligned with the STAR aligner 29 and processed using Cufflinks. 29, 30 Because KAT6A is known to be involved in P53 signaling, we examined 92 genes involved in P53 signaling. We did not observe any significant changes in TP53 mRNA levels. However, 30 genes showed significant changes in gene expression between control fibroblasts and fibroblasts from either 1-II-1 or 3-II-1( Figure 3B ), based on the q value less than the determined false discovery rate. These genes were analyzed through David Functional Annotation Resource 31,32 and showed significant enrichment for genes important in apoptosis (p < 10
À5
), nuclear transcriptional regulation (p < 10 À5 ), and cellular metabolism (p < 10 À5 ). Results from all genes are in Figure S1 and Table S4 . During development the truncated KAT6A protein exerts its damaging effect on organogenesis through dysregulated chromatin modification and P53 signaling. Mouse models with homozygous deletion of Kat6a are lethal during embryogenesis or in the perinatal period due to vascular and cardiac anomalies. Kat6a À/À mice have abnormalities in the gastrointestinal tract, cardiac defects, thymic hypoplasia, splenic hypoplasia, 33 skeletal anomalies, 21 decreased neural 34 and hematopoietic stem cell, 35 and improper B cell differentiation. 36 Similar to the clinical phenotype, there are no structural brain anomalies in Kat6a À/À mice. The loss of hematopoietic stem cells seen in mice is due to specific disruption of the catalytic HAT domain with maintenance of the transcriptional activation and repression domains at the N and C termini of Kat6a. 34, 36 To date, the children with KAT6A mutations described here do not have any defects in hematopoiesis indicating that either a single copy of WT KAT6A or that together the WT and truncated alleles are sufficient to maintain hematopoiesis. However, based on the observations in the mice, these children might experience hematological or immunological problems with time, and it would be clinically prudent to continually monitor these individuals with mutations in for evidence of hematopoietic defects. Nonsense or frameshift truncating de novo mutations in a highly homologous member of the MYST family, KAT6B (a.k.a. MYST4, MORF) have recently been described as the etiology of GPS (MIM 606170) 37, 38 and Say-Barber-
Biesecker-Young-Simpson Variant of Ohdo syndrome (SBBVYS [MIM 603736])
. 39, 40 However, the distinctive phenotypes between both syndromes are derived from a predicted differential effect of the multiple functional protein domains. The common features between GPS and SBBVYS might be due to a common loss of function of the C-terminal domains, 40 whereas phenotypes that distinguish them are hypothesized to result from expression of the truncated protein in GPS with potential gain-of-function effects. 40 Within our cohort of de novo mutations in KAT6A, we observe that proband 3-II-1 who has the p.Arg1024* variant had significant intrauterine growth retardation that was not seen in the children with the p.Arg1129* variant. We hypothesize that the differential phenotype might result from the allelic imbalance seen in the p.Arg1024* fibroblasts or secondary to effects of KAT6A targeting by the C-terminal domain. However, even among Table 2 . Continued With gastrointestinal tube dependence. For weight and length/height, Z scores were calculated using the CDC charts for children ages 2-20. Head circumference at birth was calculated using CDC charts for infants. For head circumference in children older than 2, Z score was calculated based on published data.
the individuals with identical KAT6A genotype, there is significant variability in the phenotype of individuals which further points to the importance of genetic background and environment in determining the phenotypic expression of the mutation. Beyond syndromes caused by mutations in genes encoding the MYST family of histone acetyltranferases, we reviewed genetic syndromes caused by genes that have histone acetyltransferase or deacetylase function. The major commonalities between these syndromes are microcephaly (not reported with mutations in IKBKAP or HDAC6), global developmental delay, craniofacial dysmorphism, and limb anomalies. Individuals with mutations in acetyltransferase genes more commonly display multi-organ defects, such as congenital heart disease, feeding difficulties, lung disease, and hypotonia, whereas these are less frequently observed in individuals with HDAC mutations. Individuals with mutations in HDAC genes were more likely to experience significant growth retardation and truncal obesity compared to mutations in histone acetyltransferase genes.
Given the high prevalence of mutations in KAT6A identified in our cohort of exome sequencing cases with developmental delay, we screened all individuals who underwent UCLA CES for developmental delay (n ¼ 298) for de novo mutations in 35 genes encoding histone acetyltransferases and deacetylases (Table S3) . A total of 8 de novo mutations were identified in genes that modify histone acetyl groups. Causative mutations were identified in the clinical genes KAT6B, CREBBP, HDAC8, and EP300 (reported in 6 ). At UCLA, four de novo mutations were identified in KAT6A, three reported here and a fourth de novo missense mutation in KAT6A that was identified in a child for whom CES was performed at UCLA with pontocerebellar hypoplasia. 6 However, an alternate mutation in CASK was also identified in that case and reported as more likely to be causal of the child's phenotype. It is possible that KAT6A missense variants could be a modifier of mutations in other genes. Thus, in our cases of developmental delay, we have observed three cases with de novo nonsense mutations, making the frequency of KAT6A mutations one percent (3/298) of all cases of developmental delay referred for clinical exome sequencing.
In line with the known role of KAT6A in histone acetylation, it is tempting to speculate that drug therapies might restore a more normal acetylation profile and reduce the developmental delay in individuals with KAT6A mutations. Drugs that inhibit HDAC activity are actively being studied as therapeutics in cancer, 41 neurodegenerative disorders such as Parkinson and Alzheimer disease, 41 muscular dystrophies, 42, 43 and to modulate developmental delay caused by mutations in histone acetyltransferase genes CRBBP and EP300. [44] [45] [46] However, much work needs to be done to understand complex the molecular pathways that are perturbed in individuals with KAT6A mutations and how they affect critical cellular processes in development and beyond.
In conclusion, we have identified KAT6A mutations as a frequent cause of syndromic developmental delay with microcephaly and dysmorphic features. Given the incredible rarity of most genetic syndromes, the fact that three cases had been identified at UCLA out of the first 298 CES cases performed for developmental delay makes KAT6A syndrome one of the more common causes of syndromic developmental delay. Our data demonstrates that the mutant KAT6A allele alters global acetylation of H3K9 and H3K18 and affects P53-mediated pathways in apoptosis, metabolism, and transcriptional regulation.
Accession Numbers
The ClinVar accession numbers for the KAT6A sequence reported in this paper are SCV000196747 and SCV000196748. (B) Genes in the P53 signaling pathway that show significant differences between experimental (Proband 1-II-1 or Proband 3-II-1) and control fibroblasts growing in culture were assessed using RNaseq. All genes shown were significantly increased or decreased if the q value was less than the FDR-adjusted p value of the test statistic.
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